Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates-Reference-Cited by-同舟云学术

Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates

Published:2006-12 Issue:12 Volume:50 Page:4195-4197
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wootton Mandy¹²,MacGowan Alasdair P.²,Walsh Timothy R.¹

Affiliation:

1. Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, United Kingdom

2. BCARE, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, United Kingdom

Abstract

ABSTRACT Staphylococcus aureus strains from the U.S. SENTRY Antimicrobial Surveillance Program, 2002-2003, glycopeptide-intermediate S. aureus (GISA) strains, and heterogeneous GISA (hGISA) strains were used to compare bactericidal activities of daptomycin and vancomycin using MICs and minimum bactericidal concentrations. Glycopeptide-susceptible S. aureus and hGISA strains were further studied by using time-kill curves. For all isolates, the daptomycin MIC 50 and MIC 90 are four times lower and the log drops in viable counts at 6 h and 24 h are significantly greater than those for vancomycin.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00678-06

Reference18 articles.

1. Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant Staphylococcus aureus , Vancomycin-Resistant Enterococcus faecium , and Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

2. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis.38:994-1000.

3. Cosgrove, S. E., Y. Qi, K. S. Kaye, S. Harbarth, A. W. Karchmer, and Y. Carmeli. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol.26:166-174.

4. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus

5. DeGirolami, P. C., and G. Eliopoulos. 1989. Antimicrobial susceptibility tests and their role in therapeutic drug monitoring. Clin. Lab. Med.7:499-513.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility;Journal of Nephrology;2023-08-07

2. Actions of N-acetylcysteine, daptomycin, vancomycin, and linezolid on methicillin-resistant Staphylococcus aureus biofilms in the ventriculoperitoneal shunt infections: an experimental study;Chinese Neurosurgical Journal;2022-07-05

3. Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan;International Journal of Environmental Research and Public Health;2022-02-22

4. Acute Eosinophilic Pneumonia Secondary to Daptomycin;Cureus;2021-11-09

5. Simple LC-MS/MS Methods Using Core–Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma;Therapeutic Drug Monitoring;2018-10